Independent guide
Tirzepatide Explained
Tirzepatide acts on GIP and GLP-1 receptors and is used in FDA-approved medicines for specific indications; compounded versions are not FDA-approved.
Health information: This article is educational, not medical advice. FDA-approved branded medicines and compounded preparations are different regulatory categories. Treatment choice and prescribing require an appropriate clinician.
Core facts
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
Branded product and indication matter when discussing approval, dosing and coverage.
What to verify
Compounded tirzepatide is not an FDA-approved generic equivalent.
Treatment choice requires individualized clinical review.
Sources
- HealthRX pricing
- HealthRX FAQ
- FDA: concerns with unapproved GLP-1 drugs
- FDA: 2026 compounding policy clarification
- FDA Wegovy prescribing information
- FDA Zepbound prescribing information
Provider prices and policies can change. We date-check unstable facts and distinguish provider claims from FDA or prescribing-information sources.